Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will announce its first quarter 2021 financial results on May 17, 2021. The company, focused on developing intranasal vaccines and therapies, will hold a conference call at 8:30 am ET to discuss these results and provide updates on its business. The call can be accessed via a domestic dial-in at 877-423-9813 or internationally at 201-689-8573, using the conference ID 13719206. Investors can also join the webcast to get insights into Altimmune's pipeline, including its promising COVID-19 vaccine candidate, AdCOVID™.

Positive

• Upcoming conference call for Q1 2021 results may enhance investor transparency and engagement.
• Focus on intranasal vaccines and therapies positions the company in a growing market.

Negative

• None.

GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021.

Altimmune management will host a conference call for investors beginning at 8:30 am E.T. to discuss the first quarter 2021 financial results and provide a business update.   

Conference Call Information:

Date:	Monday, May 17, 2021
Time:	8:30 am Eastern Time
Domestic Dial-in:	877-423-9813
International Dial-in:	201-689-8573
Conference ID:	13719206
Webcast:	http://public.viavid.com/index.php?id=144634

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Investor & Media Contacts:

Will Brown	Stacey Jurchison
Chief Financial Officer	Sr. Dir, Investor Relations
Phone: 240-654-1450	Phone : 410-474-8200
wbrown@altimmune.com	sjurchison@altimmune.com

FAQ

When will Altimmune report its Q1 2021 financial results?

Altimmune is set to report its Q1 2021 financial results on May 17, 2021.

What time is the Altimmune conference call for Q1 2021 results?

The conference call will take place at 8:30 am Eastern Time on May 17, 2021.

How can investors access the Altimmune Q1 2021 results conference call?

Investors can dial 877-423-9813 domestically or 201-689-8573 internationally, using conference ID 13719206.

What is the focus of Altimmune's product pipeline?

Altimmune's pipeline includes intranasal vaccines for COVID-19, anthrax, and influenza, as well as therapies for liver diseases.